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ABSTRACT:
The dynamic nature of cancer stem cells that underlie metastasis or their ability 
to switch between different cellular identities, as in EMT and MET, has profound 
implications for cancer therapy. The functional relationship between molecules 
involved in cancer cell stemness and metastasis is not clear. In this regard, our 
studies  on  hGBM  tissue  grade  IV  specimens  showed  significant  expression  of 
Twist1 and Sox2, known mesenchymal and stemness related markers, respectively, 
indicating their association with glial tumor genesis and metastasis. The glioma 
stem cells obtained from CD133+ cells demonstrated increased expression 
of  Twist1  and  Sox2  accompanied  by  significant  increase  in  the  mesenchymal 
markers such as N-cadherin, vimentin and β-catenin. Our studies on glioma stem 
cells treatment with human umbilical cord blood derived- mesenchymal stem 
cells, showed down regulation of Twist1 and Sox2 proteins, apart from other 
mesenchymal stem cell markers. Based on the in vitro experiments and in vivo 
intracranial xenograft mouse model studies, we elucidated the potential therapeutic 
role of hUCBSC in suppressing glioma cancer stemness by the induction of MET. 
INTRODUCTION
Glioblastoma multiforme represents one of the most 
frequent brain tumors with high cellular complexity. Cancer 
stem cells (CSC) are cells within tumor cells that possess 
self-renewal capacity, causing heterogeneous lineages of 
cancer cells with distinct characteristics of tumor-initiating, 
invasion, neurosphere formation and differentiation [1-
5] contributing tumor maintenance and recurrence [6, 
7]. Tumor recurrence and metastasis are identified as the 
primary cause of treatment failure in several glioblastoma 
patients. It is thus essential to understand the molecular 
mechanisms that restore the GSCs balance towards 
differentiation. 
Several investigators believed induction of EMT 
(epithelial to mesenchymal transition) is crucial for 
carcinogenesis and cancer progression [8, 9]. EMT 
of cancer cells leads to malignant carcinomas with an 
increased invasive or metastatic phenotype leading to 
tumor progression [10]. At the molecular level, EMT is 
interpreted by the down-regulation of epithelial markers 
and transcriptional induction of mesenchymal markers 
[11]. Transcription factors like Twist1 and SNAIL are 
known to be associated with cellular EMT, promoting 
cadherin switching. Twist1 is reported to be a master 
regulator of EMT and metastasis in breast, gastric, 
hepatocellular, prostate, and brain cancers including 
glioblastoma [11-21].
Further, growing evidences suggest that pathways 
regulating self-renewal are deregulated in cancer stem cells 
resulting in the continuous expansion of self-renewing 
cancer cells and tumor formation [22]. Sox2, commonly 
expressed by glioma cells and stem cells of the embryonic 
and adult brain [23] maintains proliferative potential of 
neural precursor cells, glioma-initiating cells and drives 
oncogenesis- associated aggressive tumor phenotype. 
Downregulation of Sox2 blocks proliferation and induces 
neuronal differentiation [24]. Variable percentage Oncotarget 2011; 2:  1028 - 1042 1029 www.impactjournals.com/oncotarget
Figure 1: Primary glioblastoma tumors express mesenchymal makers Twist1 and Sox2 phenotype. (A-B) Representative 
immunohistochemical staining of Twist1 and Sox2 in human GBM patient specimens and normal brain. Bar = 200 µm. Strong positivity 
of Twist1 and Sox2 was detected in five specimens (hGBMs 2,4,5,6 and 7). Negative staining was seen in normal human brain samples. 
(C-D) Specific expression of Twist1 and Sox2 in U251 and 5310 mouse xenografts models. Strong positivity of Twist1 and Sox2 was 
detected by H&E staining. Bar = 200 µm. (E) GBM tissue specimen lysates for western blot analysis were prepared as described previously 
[30]. In vivo expression was studied by loading equal amounts of protein (40 µg) from tissue lysates onto 10-12% SDS-PAGE gels. (F) 
Semi-quantitative RT-PCR analysis was done to determine the expression of various stem cell markers in human GBM-derived biopsies. 
All determinations were done in duplicate.Oncotarget 2011; 2:  1028 - 1042 1030 www.impactjournals.com/oncotarget
expression of Sox2 has been observed in gastric cancer, 
breast cancer, pancreatic cancer and glioblastoma [25], 
suggesting its relevance to cancer cell aberrant growth. 
Various experiments conducted on Sox2 have been shown 
to regulate the expression of other essential genes as 
well as its own transcription by positive feedback loops 
[26, 27]. Interestingly, several transcriptional networks 
with  vital  functions in neural stem cell populations 
appear to be co-expressed in gliomas. Studies are 
required to characterize the expression of different stem 
cell regulatory components in gliomas and to better 
understand their function in cancer progression. 
In exploring new therapeutic strategies to counter 
glioblastoma progression, our previous studies have shown 
that human umbilical cord blood stem cells (hUCBSC) 
provides a promising platform to treat glioblastoma 
[28-30]. We investigated the co-regulatory role of Sox2 
and Twist1 in GSC and their combinatorial effect on 
stemness maintenance and tumor progression. We also 
showed that restoration of glioma cancer cell EMT to 
MET pathway by hUCBSC treatment was accompanied 
by de-differentiation and dissemination of the tumor cells 
resulting in a less aggressive tumor phenotype. Our studies 
are focused on the role of hUCBSC in retarding GSC 
invasion and metastasis by suppressing the transcriptional 
activity and association of Sox2 and Twist1. To the best 
of our knowledge, this is the first study to discover that 
hUCBSC treatment per se might be significant enough 
to promote MET in vivo. However, further studies are 
needed to elucidate the underlying mechanisms.
RESULTS
Sox2 and Twist1 are expressed in human 
glioblastoma (hGBM) patient-derived specimens
Although earlier studies have indicated the 
independent expression of Sox2 [31-33]  and Twist1 
[12-14, 16, 18, 19] in different cancers including glioma 
[17, 25], the functional relationship of Sox2 and Twist1 
together in GSC remains unknown. To evaluate this 
relationship, we examined seven tissue samples of grade 
IV gliomas (from surgical biopsy specimens) labeled with 
antibodies against Sox2 and Twist1. We detected high 
Sox2 and Twist1 expression levels in these samples with 
differential expression in non-tumor areas, suggesting 
their expression in cancerous tissues and not in normal 
brain tissue (Figs. 1A-1B). (Five hGBMs 2,4,5,6 and 7 of 
seven glioma specimens expressed variable levels of both 
Sox2 and Twist1). We next studied the global expression of 
these two regulatory molecules in different cancers. Twist1 
expression was detected in medulloblastoma, meningioma, 
lung cancer, sarcoid lung cancer, and pancreatic cancer 
but not in prostate cancer (Supp. Fig. S1A) while Sox2 
expression was seen in lung cancer, sarcoid lung cancer 
and meningioma but not in medulloblastoma, pancreatic 
and prostrate cancer (Supp. Fig. S1B). We also observed 
expression of Sox2 and Twist1 in U251 and 5310 parental 
cell lines (Figs. 1C-1D). Over expression of Sox2 and 
Twist1 in glioblastoma enhances tumor cell invasion and 
metastasis, thus supporting roles for Twist1 and Sox2 in 
glial tumorigenesis and progression [34, 35]. Our present 
data indicate that both Sox2 and Twist1 expression escorts 
glial tumorigenesis and that their higher expression levels 
may be associated with grade IV glial tumors. 
To further characterize Sox2 and Twist1 association 
with malignant progression, we examined changes in 
protein and mRNA levels in hGBM samples. Western 
blotting along with RT-PCR analysis of these hGBM 
specimens demonstrated correlative expression of Sox2 
and Twist1 (Figs. 1E-1F). Nonetheless, both Twist1 and 
Sox2 levels varied considerably among the seven hGBM 
samples studied but synergistic expression was observed 
between Twist1 and Sox2. The degree of malignancy 
of these GBM tumors may in part be reflected by the 
expression levels of both Twist1 and Sox2. Epithelial 
malignancy triggers the transition from an epithelial to 
a mesenchymal cell and is characterized by the loss of 
E-cadherin and gain of N-cadherin or vimentin expression. 
Immunoblot analysis showed increased expression of 
mesenchymal markers such as N-cadherin, Vimentin and 
decrease of E-cadherin. GSC markers, including CD133, 
CD44, Msi-1 and Stro-1, showed differential expression 
in the hGBM samples when compared to human control 
brain samples (Fig. 1E). These findings from western blot 
analysis  were  confirmed  using  RT-PCR  to  identify  the 
expression of Sox2 and Twist1 along with other glioma 
stem cell markers in a panel of seven hGBM specimens 
(Fig. 1F).
GSC characterization
As shown by immunocytochemistry, GSCs obtained 
from U251, U87, 4910 and 5310 cells were positive for 
the GSC markers of proliferation, glial differentiation, and 
neuronal differentiation including CD133, CD44, GFAP, 
Ki-67, Msi-1, Nestin, Sox2, Stro-1 and Tuj1 (Fig. 2A), 
while the non-GSCs evaluated for the expression of the 
afore-mentioned markers showed reduced expression 
levels (Supp. Fig. S3D). To further assess the in vitro 
expression of Twist1 and Sox2 with regard to other 
GSC markers, we cultured CD133-sorted GSCs from 
U251, U87, 4910 and 5310 cell lines as neurospheres. 
Approximately 87.57% (U251 GSC), 69.58% (U87 GSC), 
83.75% (4910 GSC) and 28.49% (5310 GSC) of CD133-
labeled/sorted cells were positive for CD44; 80.5% (U251 
GSC), 76.36% (U87 GSC), 87.8% (4910 GSC) and 91% 
(5310 GSC) of cells were positive for Stro1; 71.2% (U251 
GSC), 64% (U87 GSC), 93.02% (4910 GSC) and 90% 
(5310  GSC)  were  positive  for  Sox2;  and  73%  (U251 Oncotarget 2011; 2:  1028 - 1042 1031 www.impactjournals.com/oncotarget
Figure 2: Evaluation of stem cell-like characteristics of U251, U87, 4910 and 5310 neurospheres. (A) Immunocytochemical 
fluorescence analysis of U251, U87, 4910 and 5310 neurospheres (passage 10). The majority of neurospheres are immunopositive for 
CD133, CD44, GFAP, Ki-67, Msi-1, Nestin, Sox2, Stro-1 and Tuj-1. Inset pictures show DAPI (blue) staining. Bar = 100 µm. (B) Double 
positive co-expression of CD133+ GSCs isolated from U251, U87, 4910 and 5310 neurospheres were studied by flow cytometry. CD133-
sorted cells from all four GSCs were labeled individually with CD44, Stro-1, Sox2 and Msi-1 with their respective antibodies. In all the 
experiments, CD133 was conjugated with Alexa Fluor-594 (red), and CD44, Stro-1, Sox2 and Msi-1 was conjugated with Alexa Fluor-488 
(green). The experiment was performed in duplicate, and error bars represent standard deviation. (C) Expression levels of various glioma 
stem cell markers and other molecules were analyzed in U251, U87, 4910 and 5310 neurospheres in comparison to their respective non-
GSC cells using semi-quantitative RT-PCR. β-actin served as an internal control for equal loading of the PCR products. Results presented 
are representative images of three independent experiments (n=3). (D-E) Western blot analysis of various neuronal and EMT makers in 
U251, U87, 4910 and 5310 neurospheres. Data presented here are a representation of three individual experiments (n=3). All cell lysates 
were obtained from cells at passage 10.Oncotarget 2011; 2:  1028 - 1042 1032 www.impactjournals.com/oncotarget
GSC),  70.58%  (U87  GSC),  73.75%  (4910  GSC)  and 
82.49% (5310 GSC) were positive for Msi1 (Fig. 2B and 
Supp. Fig. S2). The GSCs obtained from U251, U87, 4910 
and 5310 showed about 70-90% increase in the invasive 
potential while the non-GSCs showed 40-60% invasive 
potential by matrigel assay (Supp. Fig. S3A). In another 
experiment,  hUCBSC  co-culture  challenged  GSC-  and 
their respective non GSC-induced microvessel formation 
(Supp. Fig. S3B). Alternatively, RT-PCR and western blot 
analysis confirmed abundant expression of aforementioned 
stem cell markers compared to their parent counterparts 
(Figs. 2C-2D). Earlier studies have shown that CD133 
expression in tumor cells drives tumor progression [36], 
but the expression of other genes related to stemness 
on CD133-positive cells is not clearly understood. The 
increase in the expression of stemness related markers in 
GSCs (Figs. 2C-2D) was correlated with the increase in 
the expression of Sox2, Twist1, N-cadherin and Vimentin 
(Figs. 2C & 2E). 
Synergistic expression of Twist1 and Sox2 
promotes EMT
Previous reports indicate the role of Twist1 in 
increased tumor metastatic ability leading to the epithelial-
to-mesenchymal transition [11]. In the present study, we 
found that down-regulation of either Twist1 or Sox2 in 
U251, U87, 4910 and 5310 GSC resulted in phenotypic 
change from neurospheres to differentiated colonies (Fig. 
3A). 
The increased expression of N-cadherin, vimentin, 
β-catenin  and  Sox2  in  U251,  U87,  4910  and  5310 
control GSC when compared to the si-Twist-transfected 
samples is suggestive of the molecular alterations during 
mesenchymal transition (Figs. 3A & 3B). Apart from the 
EMT markers in Twist1 knockdown cells, we also observed 
a significant decrease in Sox2 levels, which is the first 
finding of this sort. To study in detail, our hypothesis that 
Twist1 regulates Sox2 expression, we transfected U251, 
U87, 4910 and 5310 GSCs with si-Sox2. We observed 
increased expression levels of E-cadherin but reduced 
N-cadherin,  vimentin,  β-catenin  and  Twist1  expression 
in the si-Sox2 transfectants (Fig. 3C). Nuclear extracts 
of U251, U87, 4910 and 5310 GSCs from both si-Twist1 
and si-Sox2 transfected samples demonstrated reduced 
expression levels when compared to their respective 
control GSCs (Figs. 3D-3E). Collectively, the above data 
suggests that the expression of both Twist1 and Sox2 in 
accord may be necessary to maintain the stemness and 
induce EMT in GSC.
Expression studies of Twist1 and Sox2 in si-Twist, 
si-Sox2 transfected GSC
To further confirm expression levels of Twist1 and 
Sox2 in both si-Twist1 and si-Sox2 transfected GSCs, we 
did FACS analysis. Contour plots were plotted to study 
frequency distribution of the expression levels of Twist1 
and Sox2. si-Twist1 reduced the expression levels of 
both Twist1 and Sox2, while si-Sox2 reduced both Sox2 
and Twist1 expression levels in all four different GSCs 
studied (Figs. 4A-4D). Overlay of the dot plots, shows 
reduced expression levels of Sox2 and Twist1 as observed 
in contour plots to provide clear understanding of the 
synergistic phenomenon. The percent expression of Twist1 
after cells were treated with si-Twist was observed to be 
reduced to 43%, 40%, 28% and 35% in U251, U87, 4910 
and 5310 GSCs, respectively. The percent expression of 
Sox2 after cells were treated with si-Twist was observed 
to  be  reduced  to  25%,  16%,  18%  and  14%  in  U251, 
U87, 4910 and 5310 GSCs, respectively (Figs. 4E-4F). 
Similarly, the percent expression of Sox2 after cells were 
treated with si-Sox2 was reduced to 29%, 27.8%, 29% and 
31% in U251, U87, 4910 and 5310 GSCs, respectively. 
The percent expression of Twist after cells were treated 
with si-Sox2 was observed to be reduced to 18.6%, 19%, 
16%  and  16%  in  U251,  U87,  4910  and  5310  GSCs, 
respectively (Figs. 4G-4H). These results are in agreement 
with our earlier findings that knockdown of Twist1 led to 
reduced expression of Sox2 and similarly, knockdown 
of Sox2 decreased Twist1 expression. These results 
suggest that their combinatorial effect may contribute to 
the maintenance of stemness and metastatic ability of the 
GSC.
Treatment of GSC with hUCBSC induces MET
Previously, we have shown that hUCBSC regulates 
glioma tumor progression [28, 29]. Taking cue from 
our previous findings, we tried to evaluate the efficacy 
of hUCBSC against U251, U87, 4910 and 5310 GSCs. 
To start with, 1x106 GSCs were co-cultured with 1x106 
hUCBSC (1:1 ratio) for 72 hrs. We observed that hUCBSC 
co-culture retrogress the aggressive mesenchymal glioma 
stem cells to their epithelial mode via differentiation 
reverting back to the parent phenotype (Fig. 5A). 
To  further  analyze  the  kinetics  of  hUCBSC-induced 
differentiation and proliferation, different phases of the 
cell cycle were determined by FACS analysis after 72 hrs. 
U251, U87, 4910 and 5310 control GSCs showed 64%, 
79.01%, 75.75%, and 75.69 % of the G0-G1 phase; 4.3%, 
12% 1.89%, and 6.1% of the S phase; and 6.38%, 1.69%, 
7.09%, and 6.82% of the G2-M phase, respectively. In 
contrast, hUCBSC-treated cells showed 34.6%, 29.75%, 
43.81%, and 43.82 % of the G0-G1 phase; 13.3%, 18% 
6.89%, and 8.1% of the S phase; and 41.22%, 40.59%, Oncotarget 2011; 2:  1028 - 1042 1033 www.impactjournals.com/oncotarget
Figure 3: Analysis of U251, U87, 4910 and 5310 GSCs treated with Twist1- and Sox2- siRNA. DAB immunocytochemistry 
was done to study the phenotypical changes of the U251, U87, 4910 and 5310 GSC when treated with (A) Twist1 siRNA and Sox2 siRNA. 
Cell lystates (40 µg protein for each sample) obtained by treating U251, U87, 4910 and 5310 GSCs with (B) siTwist and (C) siSox2 were 
loaded onto 8-12% SDS-PAGE gels, transferred onto nitrocellulose membranes, and probed with respective antibodies showing MET 
transition. (D-E) Nuclear extracts of the same samples were subjected to Western blotting (n=3). GSC (+) indicates the lysate obtained from 
scrambled vector in the immunoblots.Oncotarget 2011; 2:  1028 - 1042 1034 www.impactjournals.com/oncotarget
Figure 4: Effect of siTwist and siSox2 on Twist1 and Sox2 expression using frequency distribution contour plots. 
Approximately 1×105 U251 (A), U87 (B), 4910 (C), and 5310 (D) cells were transfected with either siTwist or si-Sox2. Samples were 
harvested after 72 hrs. siTwist1 and siSox2 expression was determined by staining with the mAb to human Twist1, Sox2 or isotype control 
mouse or goat IgG1, and then followed by a secondary antibody goat anti-mouse IgG or donkey anti-goat IgG conjugated to Alexa Fluor 
red or green dye. The background was subtracted using different isotypic controls for respective antibodies. In overlays under Figures 
4A-4D, purple color represents the negative control, green color indicates the siTwist or siSox2 treatment, orange color represents Sox2 
expression, and red color indicates Twist1 expression. Bar graph (E) represents the expression level of Twist1 in siTwist1 knock down (F) 
represents the expression level of Sox2 in siSox2 knockdown (G) represents the expression level of Sox2 in siTwist1 knock down while (H) 
represents the percent expression levels of Twist1 in siSox2 knock down as quantified from the above contour plots. Cells were analyzed 
with a FACSCalibur flow cytometer and CellQuest software. Oncotarget 2011; 2:  1028 - 1042 1035 www.impactjournals.com/oncotarget
21.17%, and 17% of the G2-M phase, respectively (Figs. 
5B-5C).  To  determine  if  the  treatment  of  hUCBSC 
resulted in a decrease in the invasive ability of GSCs, we 
monitored the effect of serum-induced invasion through 
Matrigel. GSC/ non-GSCs migrated aggressively through 
Matrigel  pores  while  hUCBSC  treatment  reduced  the 
invasive potential by around 40-70% (Supp. Fig. S3A). 
Similarly, angiogenic tube formation was reduced both in 
GSC/non-GSCs when co-cultured with hUCBSC (Supp. 
Fig. S3B).
Since it is understood that Twist1 and Sox2 
regulate the metastatic ability of tumor cells and their 
involvement in stemness preservation, we analyzed the 
hUCBSC  co-culture  treated  GSC  for  Sox2  and Twist1 
expression. Immunoblotting analysis demonstrate that 
treatment  of  U251,  U87,  4910  and  5310  GSC  with 
hUCBSC reduced N-cadherin, β-catenin, vimentin, Sox2 
and Twist1 expression, with increased E-cadherin levels 
indicative of MET course (Fig. 5D). To further explore 
the effect of hUCBSC on GSCs, we looked for changes 
in cellular functions frequently associated with EMT by 
hUCBSC treatment. We examined the expression levels 
of the above mentioned proteins in U251 and 5310 GSC 
xenografts by western blot analysis; the expression levels 
of mesenchymal markers were decreased upon hUCBSC 
treatment (Fig. 5E). RT-PCR results confirmed our above 
results obtained from western blot analysis (Fig. 5F). 
Figure 5: Effect of hUCBSC on GSC. (A) Co-culture experiments showing induction of MET transition by hUCBSC in GSCs. (B) 
Various stages of cell cycle of GSCs influenced by hUCBSC. In all of the GSCs, cell cycle was arrested at the G2-M stage. (C) Bar graph 
showing the results of (B). Western blot analysis showing MET pathway molecules in U251, U87, 4910 and 5310 GSCs when co-cultured 
with hUCBSC (D) in vitro (72 hrs) and (E) in vivo. (F) Semi-quantitative RT-PCR analysis showing MET transition of GSCs.Oncotarget 2011; 2:  1028 - 1042 1036 www.impactjournals.com/oncotarget
hUCBSC treatment inhibits Sox2 and Twist1 
expression in the intracranial GSC induced 
tumors of mice
To determine the analeptic of hUCBSC on GSC tumor 
formation in vivo, athymic nude mice were injected with 
U251 and 5310 GSCs (1×105) in the left frontal lobe. Mice 
injected with U251 and 5310 GSCs showed detectable 
tumor characteristics, such as hunch back appearance, 
paralyzed limbs, severe weight loss and neurologic pain 
within 12-18 days. After three weeks, an equal number of 
hUCBSC (1×105) were injected into the right lobe of the 
mice, already having GSC induced tumors. The hUCBSC 
treatment showed regression in GSC induced tumors and 
tumor  development.  Mice  treated  with  only  hUCBSC 
did not form tumors for 120 days (Data not shown). 
Pathological examination of GSC induced tumors in the 
nude mice showed a vast necrotic area associated with the 
tumor tissues; hUCBSC treatment significantly reduced 
GSC induced tumor volumes (Supp. Fig. S3C). The tumor 
volumes were reduced to 65-75% in U251 and 75-90% 
in 5310 GSC- treated mice upon hUCBSC treatment as 
evidenced by H&E staining (Fig. 6C).  To corroborate 
our findings and to extend our results from hGBM tissue 
specimens, we analyzed the expression of both Twist1 
and Sox2 by immunohistochemistry. Adjacent sections 
were used to study the expression of both Twist1 and 
Sox2. High expression of Twist1 and Sox2 was observed 
in the necrotic regions of U251 and 5310 GSC induced 
tumor, while hUCBSC-treated U251 and 5310 xenografts 
showed reduced or no expression of either Twist1 or Sox2 
in individual experiments (Fig 6C).
As  evidenced  by  the  significant  increase  in  the 
expression of both Twist1 and Sox2 in the necrotic tumor 
areas, and their co-regulatory effect in siRNA transfectants, 
we next asked whether this expression is the co-regulatory 
mechanism necessitated by the interaction between 
Twist1 and Sox2. Initial experiments in this direction 
were targeted at neurospheres at the in vitro level. Control 
GSCs obtained from U251, U87, 4910 and 5310 showed 
clear interaction and co-localization between Twist1 
and  Sox2  while  hUCBSC  treatment  showed  decreased 
expression and co-localization of both these proteins (Fig. 
6A). These results prompted us to study co-localization 
of these proteins in an in vivo xenograft model. U251 and 
5310 GSC control tissue samples showed co-localization 
of  Sox2  with  Twist1  which  was  significantly  reduced 
upon hUCBSC treatment (Fig. 6B). The association of 
transcription factors, Sox2 (responsible for stemness) and 
Twist1 (responsible for EMT) thus provides a platform 
to correlate the stem cell pathway with EMT pathway, 
which can be further studied to address potential targets 
for glioblastoma cure.
DISCUSSION
Cancer stem cells render abnormal growth, 
frequency and radio-resistance in malignant glioblastoma. 
Therapeutic strategies in treating glioblastoma require 
a better understanding of the mechanisms that promote 
stem cell maintenance that sustain tumor growth. Elias, 
et al. [34] proposed neural precursor cells as the likely 
targets for malignant transformation and showed that 
deregulation of the self-renewal capacity of normal stem 
Gene Forward Primer Reverse Primer
CD133 5’CCAAGTTCTACCTCATGTTTGG 3’ 5’ACCAACAGGGAGATTGCAAAGC3’
CD44 5’ AATCCCTGCTACCAATATGGACT  3’ 5’ AGCCTTCAGAATGATTTGGGTC  3’
N-cadherin 5’CAACTTGCCAGAAAACTCCAGG 3’ 5’ ATGAAACCGGGCTATCTGCTC   3’
E-cadherin 5’ CGAGAGCTACACGTTCACGG  3’ 5’ GGCCTTTTGACTGTAATCACACC  3’
Sox2 5’ CACAACTCGGAGATCAGCAA  3’ 5’ CTCCGGGAAGCGTGTACTTA   3’
Twist1 5’CGGACAAGCTGAGCAAGATT 3’ 5’ CCTTCTCTGGAAACAATGAC  3’
Nestin 5’ GGCATCCTCACCCTGAAGTA  3’ 5’ CTTGGGGTCCTGAAAGCTG  3’
β-catenin 5’GAAACGGCTTTCAGTTGAG 3’ 5’ CTGGCCATATCCACCAGAGT  3’
Vimentin 5’GAACGCCAGATGCGTGAAATG3’ 5’CCAGAGGGAGTGAATCCAGATTA3’
β-actin 5’GGCATCCTCACCCTGAAGTA3’ 5’GGGGTGTTGAAGGTCTCAAA3’
Table 1: PCR primers.Oncotarget 2011; 2:  1028 - 1042 1037 www.impactjournals.com/oncotarget
Figure 6: Twist1 co-expresses with Sox2 in U251, U87, 4910 and 5310 GSCs. (A) Immunostaining analysis from neurospheres 
generated from GSC-enriched populations (U251, U87, 4910 and 5310 cells) shows Twist1 staining that appears to correlate with high 
Sox2 expression. Photographs depicted show Twist1 (red) is co-expressed/associated with Sox2 (green). All nuclei are counterstained with 
DAPI in blue. Scale bars represent 100 µm. (B) Immunostaining of GBM mouse xenografts (U251 and 5310) demonstrate that Twist1 (red) 
is expressed in the necrotic area and is co-expressed with Sox2 (green). Scale bars represent 50 µm. DAB immunohistochemical analysis 
of Twist1 and Sox2 expression in U251 GSC and 5310 GSC xenografts in nude mice brains. (C) Representative microphotographs of 
U251 and 5310 GSCs injected intracranially, which show infiltrative/migratory nature of xenograft-derived tumors. Insets in figures are 
representative H&E stained sections. Immunohistochemical staining was done using specific antibodies for Twist1 and Sox2 (dark brown 
in color). Scale bar represents 100 µm.Oncotarget 2011; 2:  1028 - 1042 1038 www.impactjournals.com/oncotarget
cells resulted in stable augmentation of self-renewing 
cancer cells and tumor formation. Investigations to study 
this tumorigenic process will provide a powerful tool to 
uncover new targets for glioma therapeutic intervention. 
On par with the available evidence, it is understood that 
cancer stem cells (CSC) play an important role in tumor 
initiation, growth, invasion and recurrence. Therefore, 
identification and study of CSC will provide insights into 
better understanding of brain tumors and their cellular 
targets. In this study, we have obtained GSCs from U251, 
U87, 4910 and 5310 cell lines using the surface protein 
CD133 and FACS sorting as reported previously [37-39]. 
In the present study, we show that malignant human 
grade IV gliomas display significant expression of Twist1 
and Sox2. Twist1 expression was observed in hGBMs 
as well as in medulloblastoma, meningioma, lung and 
pancreatic cancer specimens, while Sox2 expression 
was observed in hGBM specimens along with that of 
meningioma, lung and pancreatic cancers. These results 
indicate the participation of both Twist1 and Sox2 in 
the genesis of a wide range of neuroectodermal tumors. 
Twist1 encourages cancer cell survival and tumor 
progression by increasing resistance to cytotoxic therapies 
resulting in increased cellular proliferation [40]. Twist1 
is considered to be a key player of EMT, a metastatic 
cascade in which epithelial cells take over a mesenchymal 
phenotype [10]. EMT phenotype expresses cancer stem-
like cells signatures associated with tumor recurrence 
and a drug-resistant phenotype [41]. Immunoblotting 
analysis conducted on the hGBM specimens have shown 
reduced epithelial E-cadherin expression and upregulated 
mesenchymal N-cadherin, vimentin, β-catenin and Twist1, 
suggesting the EMT mode. High expression levels of 
other stem cell markers such as CD44, Msi-1, Stro-1, and 
EMT markers, such as Sox2, Twist1, vimentin suggested 
an invasive phenotype. The synergistic up-regulation 
of Twist1 and Sox2 expression in hGBM specimens 
may instigate E-cadherin replacement by N-cadherin 
expression triggering cadherin switching [42, 43].
Numerous lines of evidences suggest that the Twist1 
regulates programmed cell death and induces apoptosis 
[44, 45]. Moreover, it has been observed that transfection 
of Bel7402 (highly expressing Twist1) cells with Twist1 
shRNA plasmid resulted in suppression of Twist1 
expression and subsequent inhibition of cell invasion 
and migration in vitro, indicating its possible role in 
tumor cell plasticity [46]. The widespread expression of 
Twist1 in various cancer phenotypes suggests its action 
upon a diverse set of downstream target genes, depending 
upon the tissue, to elicit a variety of cellular responses. 
The chimeric nature of beta-Helix loop Helix (bHLH) 
proteins, such as Twist1 are implicated to possibly 
combine heterodimerically with other bHLH proteins to 
activate or repress diverse downstream targets generating 
different types of biological responses [47]. Cimadamore 
et al., [48] reported that knockdown of Sox2, the 
SRY (sex-determining region)-box 2 gene, resulted in 
downregulation of proneural bHLH transcription factors.
Twist1-mediated molecular changes in our study 
provided important insight into its role in understanding 
mesenchymal change with genes related to EMT being 
upregulated in U251, U87, 4910 and 5310 GSCs. Since 
we observed the co-expression of Sox2 along with Twist1, 
further studies are warranted to examine their role in 
acquiring an invasive malignant phenotype. Knockdown 
of Twist1 reduced the expression levels of Sox2, while 
knockdown of Sox2 reduced the expression levels of 
Twist1. In both experiments, increased expression of 
E-cadherin was observed, which suggests that both Twist1 
and Sox2 function in harmony and that their concurrence 
is essential for the maintenance of tumor plasticity. 
Inhibition of Twist1 or Sox2 expression by their specific 
siRNAs resulted in differentiation of GSC formation 
and growth and is suggestive of the above discussed 
mechanism. 
Targeted migration of mesenchymal stem cells 
(MSCs) to tumors makes them a very promising strategy for 
anti-tumor therapy [49]. Previously, we have demonstrated 
the potential therapeutic applications of hUCBSC in the 
treatment of gliomas [28, 29]. In addition, with increased 
understanding of the mechanistic underpinnings of 
MSC action, the potential for enhancing MSC-targeted 
therapies appears promising. This report provides a strong 
evidence that hUCBSC inhibit the metastatic and invasive 
potential of U251, U87, 4910 and 5310 GSCs. Co-culture 
of hUCBSC with these GSCs changed their morphology 
and clearly reduced their migration and invasion abilities. 
We also showed that hUCBSC induced MET in U251, 
U87, 4910 and 5310 GSCs, which might be responsible 
for inhibition of metastasis-related abilities. 
It  appears  that  hUCBSC  counteract  and  repress 
Twist1 expression by increasing E-cadherin levels, a 
phenomenon generally observed at sites of EMT. Our 
present  data  demonstrated  the  ability  of  hUCBSC  to 
inhibit GSC phenotypes in co-culture experiments both in 
vitro and in vivo. Immunoblotting experiments showed a 
decrease in the expression levels of both Twist1 and Sox2 
along with other EMT markers, suggesting that hUCBSC 
treatment reversed the EMT to MET. Based on all our 
findings, we propose that hUCBSC inhibit GSC invasion, 
migration by suppressing key molecules involved in 
EMT. These actions resulted in induction of a MET state, 
which is a key step in reversal and treatment of the cellular 
metastatic process.
In  conclusion,  for  the  first  time,  we  showed  that 
interactive and co-regulatory role of Twist1 and Sox2 
necessary to maintain glioma stemness was inhibited by 
hUCBSC. Here, hUCBSC was administered to study key 
aspects in treating the glioma stem cell machinery. We 
engineered hUCBSC near the tumor site and observed 
that hUCBSC are effective in regressing tumor growth 
in the intracranial xenograft mouse model. Based on Oncotarget 2011; 2:  1028 - 1042 1039 www.impactjournals.com/oncotarget
our findings, we conclude that hUCBSC can be used as 
a means of therapy and will be of great interest for the 
clinical application of stem cell-based cancer therapy.
MATERIALS AND METHODS
Tumor samples
Glioblastoma specimens were obtained during 
autopsies of glioblastoma patients within 24 hrs of death 
or from patients who underwent surgery at Saint Francis 
Medical Center (Peoria, IL). All samples were collected 
under protocols approved by the UICOMP (Peoria, IL) 
Institutional Review Board. All tumors without prior 
evidence of progression from a lower-grade tumor were 
clinically classified as primary glioblastoma. 
Culture of hUCBSC
Human umbilical cord blood stem cells were isolated 
as described previously (See supplemental methods) [29]. 
Enrichment for glioma stem cells
Human glioma cell lines parental and non-GSC 
(U251 and U87) and xenografts (4910 and 5310) were 
cultured using conventional tissue culture media: DMEM/
RPMI-1640  (Hyclone,  Logan,  UT)  supplemented  with 
10% fetal bovine serum (Gibco BRL, Grand Island, 
NY), 100 units/mL penicillin/streptomycin (Lonza, 
Walkersville,  MD).  GBM  neurospheres  of  U87,  U251, 
and xenografts 4910, 5310 were cultured in neurobasal 
medium supplemented with N2 (1%), B27 (1%), 20 
ng/mL of bFGF and EGF, 10 ng/mL of LIF (Millipore, 
Billerica, MA)[50]. Experiments for the present study 
were conducted using the neurospheres obtained between 
the 5-14th passages.
Immuno- cyto- histochemical staining
Experiments were performed to detect the expressi1 
on of various stem cell markers CD133, CD44, Msi-1, 
Stro1, Nestin, Sox2, Ki-67, GFAP and Tuj-1 in both GSC 
and non-GSCs (see Supplemental methods). 
Semi-Quantitative RT-PCR
 Total RNA (5 μg) from cells, brains or tumor samples 
extracted using Qiagen RNeasy mini kit (Valencia, CA) 
was reverse-transcribed using the Transcriptor First 
Strand cDNA Synthesis Kit (Roche, Indianapolis, IN). 
(See Supplementary methods) 
CD133 sorting, cell cycle analysis
 GSCs obtained from U251, U87, 4910 and 5310 
cells dissociated by trituration into single cell suspension 
were incubated for 60 min at 4°C with anti-CD133 
phycoerythrin (PE)-conjugated antibody (clone AC133-
PE, mouse IgG1; Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. 
PE-conjugated mouse IgG1 isotype antibody was used 
as control. The cells re-suspended in 0.5 mL PBS-BSA 
were analyzed and sorted by flow cytometry. Acquisition 
was performed on a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA) and viable cells were analyzed 
with CellQuest software. In a separate experiment, the 
CD133-positive cells were labeled with anti-CD44, 
anti-Stro-1, anti-Msi-1 and anti-Sox2 in independent 
experiments using a similar staining protocol. The control 
for each sample was prepared identically except that an 
isotype-specific antibody was used. Progression through 
different cell cycle phases in U251, U87, 4910 and 5310 
cells alone and in co-culture with hUCBSC for 72 hrs 
was monitored by flow cytometric analysis of the DNA 
content of cell populations stained with propidium iodide 
(BioSure, Grass Valley, CA). 
Matrigel invasion and In vitro angiogenesis assay
 The Matrigel invasion assay and tumor conditioned 
medium-induced microtubule network formation were 
studied in U251, U87, 4910 and 5310 GSC, non-GSC 
alone or in co-culture with hUCBSC (See supplemental 
methods and materials).
siRNA-based knockdown of Twist1 and Sox2
  The siRNA targeting human Twist1 (sc-38604), 
Sox2 (sc-38408) and scrambled negative control RNA 
(Santa Cruz, CA).  were used to transfect U251, U87, 
4910 and 5310 GSCs (2.5×105 cells) using 6 µL of Fugene 
HD reagent (Roche, Indianapolis, IN). The siRNA/Fugene 
HD complex was added to the GSCs and the transfection 
was carried out for 48-72 hrs. Nuclear extracts were 
prepared from these siRNA-transfected samples using a 
nuclear extraction kit from Panomics, Inc. (Fremont, CA) 
according to the manufacturer’s instructions. 
Contour plot FACS analysis
  Twist1 and Sox2 expression was measured by 
intracellular protein staining using antibodies specific for 
human Twist1 and Sox2 (Santa Cruz Technologies, Santa 
Cruz, CA). The Twist1 siRNA- or Sox2 siRNA-transfected 
cells were incubated for 1 hr with gene-specific Twist1 or 
Sox2. Twist1 expression in si-Sox2-treated samples and Oncotarget 2011; 2:  1028 - 1042 1040 www.impactjournals.com/oncotarget
Sox2 expression in si-Twist1 treated samples were studied 
by measuring cellular fluorescence using the FACSCalibur 
flow cytometer (Becton Dickinson, San Jose, CA). 
Western blotting
 GBM parental or stem cells alone or in co-culture 
with hUCBSC for 72 hrs were collected, lysed in RIPA 
buffer and then resolved via SDS-PAGE (See supplemental 
methods). 
Intracranial administration of GSC and hUCBSC
  Glioma stem cells were injected intracerebrally 
into the left side of the brain of nude mice with 10 µL 
aliquots of U251 and 5310 GSC (1×105) under isofluorane 
anesthesia with the aid of a stereotactic frame. Three 
weeks after tumor implantation, hUCBSC were injected 
towards the right side of the brain in 1:1 ratio. Six mice 
from  each  group  were  sacrificed  by  cardiac  perfusion 
with 4% formaldehyde in PBS, and paraffin sections were 
prepared. Sections were stained with H&E to visualize 
tumor cells and to examine tumor volume. The sections 
were blindly reviewed and scored semi-quantitatively for 
tumor size. The average visible tumor area per section 
integrated to the number of sections was calculated using 
the formula 1/6 II (Rmax) × (Rmin)2, where Rmax 
and Rmin are the maximum and minimum tumor radii, 
respectively. The calculated tumor volume was compared 
between controls and treated groups. 
ACKNOWLEDGEMENTS
The authors thank Peggy Mankin and Noorjehan 
Ali for their technical assistance, Shellee Abraham for 
manuscript preparation, Diana Meister and Sushma Jasti 
for manuscript review. The authors declare that no conflict 
of interest exists with this manuscript.
REFERENCE LIST
1.   Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De 
Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A. Isolation 
and characterization of tumorigenic, stem-like neural 
precursors from human glioblastoma. Cancer Research. 
2004: 64: 7011-21.
2.   Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith 
M, Geschwind DH, Bronner-Fraser M, Kornblum HI. 
Cancerous stem cells can arise from pediatric brain tumors. 
Proceeding  of  the  National  Academy  of  Science  USA. 
2003: 100: 15178-83.
3.   Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, 
Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, 
Rich JN. Hypoxia-inducible factors regulate tumorigenic 
capacity of glioma stem cells. Cancer Cell. 2009: 15: 501-
13.
4.   Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide 
T, Henkelman RM, Cusimano MD, Dirks PB. Identification 
of human brain tumour initiating cells. Nature. 2004: 432: 
396-401.
5.   Vescovi AL, Galli R, Reynolds BA. Brain tumour stem 
cells. Nature Reviews Cancer. 2006: 6: 425-36.
6.   Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland 
AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells 
promote radioresistance by preferential activation of the 
DNA damage response. Nature. 2006: 444: 756-60.
7.   Hambardzumyan D, Squatrito M, Holland EC. Radiation 
resistance and stem-like cells in brain tumors. Cancer Cell. 
2006: 10: 454-6.
8.   Wu Y, Zhou BP. New insights of epithelial-mesenchymal 
transition in cancer metastasis. Acta Biochimica et 
Biophysica. Sinica. (Shanghai). 2008: 40: 643-50.
9.   Yang J, Weinberg RA. Epithelial-mesenchymal transition: 
at the crossroads of development and tumor metastasis. 
Developmental. Cell. 2008: 14: 818-29.
10.  Thiery JP. Epithelial-mesenchymal transitions in tumour 
progression. Nature Reviews Cancer. 2002: 2: 442-54.
11.  Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson 
RA, Come C, Savagner P, Gitelman I, Richardson A, 
Weinberg RA. Twist, a master regulator of morphogenesis, 
plays an essential role in tumor metastasis. Cell. 2004: 117: 
927-39.
12.   Casas E, Kim J, Bendesky A, Ohno-Machado L, Wolfe CJ, 
Yang J. Snail2 is an essential mediator of Twist1-induced 
epithelial mesenchymal transition and metastasis. Cancer 
Research. 2011: 71: 245-54.
13.   Jeronimo C, Esteller M. DNA methylation markers for 
prostate cancer with a stem cell twist. Cancer Prevention 
Research. (Phila). 2010: 3: 1053-5.
14.  Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang 
X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, 
Wang X. Up-regulation of TWIST in prostate cancer and its 
implication as a therapeutic target. Cancer Research. 2005: 
65: 5153-62.
15.   Lee TK, Poon RT, Yuen AP, Ling MT, Kwok WK, Wang 
XH, Wong YC, Guan XY, Man K, Chau KL, Fan ST. Twist 
overexpression correlates with hepatocellular carcinoma 
metastasis through induction of epithelial-mesenchymal 
transition. Clinical Cancer Research. 2006: 12: 5369-76.
16.   Ma JL, Han SX, Zhu Q, Zhao J, Zhang D, Wang L, Lv Y. 
Role of Twist in vasculogenic mimicry formation in hypoxic 
hepatocellular carcinoma cells in vitro. Biochemical and 
Biophysical Research Communication. 2011: 408: 686-91.
17.   Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford 
RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, 
Gonzalez-Herrero I, Sanchez-Garcia I, Silber JR, Horner 
PJ, Rostomily RC. TWIST1 promotes invasion through Oncotarget 2011; 2:  1028 - 1042 1041 www.impactjournals.com/oncotarget
mesenchymal change in human glioblastoma. Molecular 
Cancer. 2010: 9: 194.
18.  Mironchik Y, Winnard PT, Jr., Vesuna F, Kato Y, Wildes 
F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van 
DP, Burger H, Glackin C, Raman V. Twist overexpression 
induces in vivo angiogenesis and correlates with 
chromosomal instability in breast cancer. Cancer Research. 
2005: 65: 10801-9.
19.   Ru GQ, Wang HJ, Xu WJ, Zhao ZS. Upregulation of twist 
in gastric carcinoma associated with tumor invasion and 
poor prognosis. Patholology Oncology Research. 2011: 17: 
341-7.
20.   Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, 
Chan  KW.  Significance  of  TWIST  and  E-cadherin 
expression in the metastatic progression of prostatic cancer. 
Histopathology. 2007: 50: 648-58.
21.   Zhang Z, Xie D, Li X, Wong YC, Xin D, Guan XY, Chua 
CW, Leung SC, Na Y, Wang X. Significance of TWIST 
expression and its association with E-cadherin in bladder 
cancer. Human Pathology. 2007: 38: 598-606.
22.   Ge Y, Zhou F, Chen H, Cui C, Liu D, Li Q, Yang Z, Wu 
G, Sun S, Gu J, Wei Y, Jiang J. Sox2 is translationally 
activated by eukaryotic initiation factor 4E in human 
glioma-initiating cells. Biochemical and Biophysical 
Research Communication. 2010: 397: 711-7.
23.   Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, 
Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G. SOX2 
silencing in glioblastoma tumor-initiating cells causes stop 
of proliferation and loss of tumorigenicity. Stem Cells. 
2009: 27: 40-8.
24.  Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, Zheng S, 
Hood L, Goodlett DR, Foltz G, Lin B. The SOX2 response 
program in glioblastoma multiforme: an integrated ChIP-
seq, expression microarray, and microRNA analysis. BMC. 
Genomics. 2011: 12: 11.
25.  Schmitz M, Temme A, Senner V, Ebner R, Schwind S, 
Stevanovic S, Wehner R, Schackert G, Schackert HK, 
Fussel M, Bachmann M, Rieber EP, Weigle B. Identification 
of SOX2 as a novel glioma-associated antigen and potential 
target for T cell-based immunotherapy. Britich Journal of 
Cancer. 2007: 96: 1293-301.
26.  Boer B, Kopp J, Mallanna S, Desler M, Chakravarthy H, 
Wilder PJ, Bernadt C, Rizzino A. Elevating the levels of 
Sox2 in embryonal carcinoma cells and embryonic stem 
cells inhibits the expression of Sox2:Oct-3/4 target genes. 
Nucleic Acids Research. 2007: 35: 1773-86.
27.  Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, 
Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner 
RG, Gifford DK, Melton DA, Jaenisch R, Young RA. Core 
transcriptional regulatory circuitry in human embryonic 
stem cells. Cell. 2005: 122: 947-56.
28.  Dasari VR, Velpula KK, Kaur K, Fassett D, Klopfenstein 
JD, Dinh DH, Gujrati M, Rao JS. Cord Blood Stem Cell-
Mediated Induction of Apoptosis in Glioma Downregulates 
X-Linked Inhibitor of Apoptosis Protein (XIAP). PLoSOne. 
2010: 5: e11813.
29.   Velpula KK, Dasari VR, Tsung AJ, Gondi CS, Klopfenstein 
JD, Mohanam S, Rao JS. Regulation of glioblastoma 
progression by cord blood stem cells is mediated by 
downregulation of cyclin D1. PlosOne. 2011a: 6: e18017.
30.   Velpula KK, Dasari VR, Tsung AJ, Dinh DH, Rao JS. 
Transcriptional repression of MAD-MAX complex by 
human umbilical cord blood stem cells downregulates ERK 
in  glioblastoma.  Stem  Cells  and  Development.  2011b: 
doi:10.10891scd.2011.0424.
31.   Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang 
X, Wang Y, Zhang Y, Shang Y. The molecular mechanism 
governing the oncogenic potential of SOX2 in breast 
cancer. Journal of Biological Chemistry. 2008: 283: 17969-
78.
32.   Park ET, Gum JR, Kakar S, Kwon SW, Deng G, Kim YS. 
Aberrant expression of SOX2 upregulates MUC5AC gastric 
foveolar mucin in mucinous cancers of the colorectum and 
related lesions. International Journal of. Cancer. 2008: 122: 
1253-60.
33.   Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani 
Y. Histopathologic evaluation of stepwise progression of 
pancreatic carcinoma with immunohistochemical analysis 
of gastric epithelial transcription factor SOX2: comparison 
of expression patterns between invasive components 
and cancerous or nonneoplastic intraductal components. 
Pancreas. 2006: 32: 164-70.
34.  Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, 
Morrison RS, Manning TC, Silbergeld DL, Glackin CA, 
Reh TA, Rostomily RC. TWIST is expressed in human 
gliomas and promotes invasion. Neoplasia. 2005: 7: 824-
37.
35.   Wegner M, Stolt CC. From stem cells to neurons and 
glia:  a  Soxist’s  view  of  neural  development.  Trends  in 
Neuroscience. 2005: 28: 583-8.
36.   Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler 
CE,  MacSwords  J,  Wu  Q,  Vasanji  A,  McLendon  RE, 
Hjelmeland AB, Rich JN. Integrin alpha 6 regulates 
glioblastoma stem cells. Cell Stem Cell. 2010: 6: 421-32.
37.   Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, 
Mimori K, Matsumoto T, Inoue H, Kuwano H, Mori M. 
Biological and genetic characteristics of tumor-initiating 
cells in colon cancer. Annals of Surgical Oncology. 2008: 
15: 638-48.
38.   Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu 
L, Irvin D, Black KL, Yu JS. Analysis of gene expression 
and chemoresistance of CD133+ cancer stem cells in 
glioblastoma. Molecular Cancer. 2006: 5:67.: 67.
39.  Pfenninger CV, Roschupkina T, Hertwig F, Kottwitz D, 
Englund E, Bengzon J, Jacobsen SE, Nuber UA. CD133 
is not present on neurogenic astrocytes in the adult 
subventricular zone, but on embryonic neural stem cells, Oncotarget 2011; 2:  1028 - 1042 1042 www.impactjournals.com/oncotarget
ependymal cells, and glioblastoma cells. Cancer Research. 
2007: 67: 5727-36.
40.  Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, 
Lee DT, Wong YC. Identification of a novel function of 
TWIST, a bHLH protein, in the development of acquired 
taxol resistance in human cancer cells. Oncogene. 2004: 23: 
474-82.
41.  Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou 
AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. 
The epithelial-mesenchymal transition generates cells with 
properties of stem cells. Cell. 2008: 133: 704-15.
42.   Alexander NR, Tran NL, Rekapally H, Summers CE, 
Glackin C, Heimark RL. N-cadherin gene expression in 
prostate carcinoma is modulated by integrin-dependent 
nuclear translocation of Twist1. Cancer Research. 2006: 
66: 3365-9.
43.   Maeda M, Johnson KR, Wheelock MJ. Cadherin switching: 
essential for behavioral but not morphological changes 
during an epithelium-to-mesenchyme transition. Journal of 
Cell Science. 2005: 118: 873-87.
44.   Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin 
E, Jallas AC, Combaret V, Krause A, Leissner P, Puisieux 
A. Oncogenic cooperation between H-Twist and N-Myc 
overrides failsafe programs in cancer cells. Cancer Cell. 
2004: 6: 625-30.
45.   Yousfi  M,  Lasmoles  F,  El  G,  V,  Marie  PJ.  Twist 
haploinsufficiency in Saethre-Chotzen syndrome induces 
calvarial osteoblast apoptosis due to increased TNFalpha 
expression and caspase-2 activation. Human. Molecular 
Genetics. 2002: 11: 359-69.
46.   Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang 
XH, Du J, Liu YX, Sun BC. Expression and functional 
significance of Twist1 in hepatocellular carcinoma: its role 
in vasculogenic mimicry. Hepatology. 2010: 51: 545-56.
47.  Franco HL, Casasnovas J, Rodriguez-Medina JR, Cadilla 
CL. Redundant or separate entities?--roles of Twist1 and 
Twist2 as molecular switches during gene transcription. 
Nucleic Acids Research. 2011: 39: 1177-86.
48.    Cimadamore F, Fishwick K, Giusto E, Gnedeva K, 
Cattarossi G, Miller A, Pluchino S, Brill LM, Bronner-
Fraser M, Terskikh AV. Human ESC-derived neural crest 
model reveals a key role for SOX2 in sensory neurogenesis. 
Cell Stem Cell. 2011: 8: 538-51.
49.   Kosztowski  T,  Zaidi  HA,  Quinones-Hinojosa  A. 
Applications of neural and mesenchymal stem cells in 
the treatment of gliomas. Expert Review of Anticancer 
Therapy. 2009: 9: 597-612.
50.  Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, 
Pastorino S, Purow BW, Christopher N, Zhang W, Park 
JK, Fine HA. Tumor stem cells derived from glioblastomas 
cultured in bFGF and EGF more closely mirror the 
phenotype and genotype of primary tumors than do serum-
cultured cell lines. Cancer Cell. 2006 May;9(5):391-403.